Quiz

• Assessment of the patient's inflammatory phenotype is

recommended once a patient is diagnosed with severe asthma and
referred to a specialist for treatment. According to the GINA report,
determining if the patient has type 2 or non–type 2 severe asthma
can help optimize treatment choice with a targeted therapy.
• Learn more about severe asthma phenotypes.
• According to the GINA report, a sputum eosinophil count ≥ 2% is one of several
indicators that a patient who is taking high-dose ICS or daily OCS may have type 2
inflammation. The other signs of possible type 2 inflammation include:
• Blood eosinophil count ≥ 150/μL
• Fractional exhaled nitric oxide (FeNO) level ≥ 25 parts per billion
• Asthma that is clinically allergen driven
• Patients requiring maintenance OCS therapy (although biomarkers of type 2
inflammation such as blood eosinophil count, sputum eosinophil count, and FeNO
level are often suppressed by OCS)
• For more on the GINA 2019 update on severe asthma, refer to Part E of the
report, beginning on page 84.